172 related articles for article (PubMed ID: 1992185)
21. Iatrogenic Creutzfeldt-Jakob disease.
Rappaport EB
Neurology; 1987 Sep; 37(9):1520-2. PubMed ID: 3306455
[TBL] [Abstract][Full Text] [Related]
22. Pituitary growth hormone from human cadavers: neurologic disease in ten recipients.
Rappaport EB; Graham DJ
Neurology; 1987 Jul; 37(7):1211-3. PubMed ID: 3474545
[TBL] [Abstract][Full Text] [Related]
23. Creutzfeldt-Jakob disease and blood transfusion.
Esmonde TF; Will RG; Slattery JM; Knight R; Harries-Jones R; de Silva R; Matthews WB
Lancet; 1993 Jan; 341(8839):205-7. PubMed ID: 8093499
[TBL] [Abstract][Full Text] [Related]
24. [Psychiatric manifestations of a new variant of Creutzfeldt-Jakob disease. Apropos of a case].
Dervaux A; Vicart S; Lopes F; Le Borgne MH
Encephale; 2001; 27(2):194-7. PubMed ID: 11407273
[TBL] [Abstract][Full Text] [Related]
25. Creutzfeldt-Jakob disease: current U.S. policy to further reduce the possible risk of transmission by transfusion.
Menache D; O'Malley JP
Biologicals; 1996 Sep; 24(3):277-83. PubMed ID: 8978926
[TBL] [Abstract][Full Text] [Related]
26. [A patient with Creutzfeldt-Jakob disease following treatment with human growth hormone].
Roos RA; Wintzen AR; Will RG; Ironside JW; van Duinen SG
Ned Tijdschr Geneeskd; 1996 Jun; 140(22):1190-3. PubMed ID: 8692356
[TBL] [Abstract][Full Text] [Related]
27. Mortality, neoplasia, and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom.
Buchanan CR; Preece MA; Milner RD
BMJ; 1991 Apr; 302(6780):824-8. PubMed ID: 2025705
[TBL] [Abstract][Full Text] [Related]
28. A statistical model to identify the contaminated lots implicated in iatrogenic transmission of Creutzfeldt-Jakob disease among French human growth hormone recipients.
Huillard d'Aignaux J; Alpérovitch A; Maccario J
Am J Epidemiol; 1998 Mar; 147(6):597-604. PubMed ID: 9521187
[TBL] [Abstract][Full Text] [Related]
29. A further British case of growth hormone induced Creutzfeldt-Jakob disease.
Ellis CJ; Katifi H; Weller RO
J Neurol Neurosurg Psychiatry; 1992 Dec; 55(12):1200-2. PubMed ID: 1479400
[TBL] [Abstract][Full Text] [Related]
30. [Acquired Creutzfeldt-Jakob disease (CJD)--Kuru, iatrogenic CJD, variant CJD].
Sanjo N
Nihon Rinsho; 2007 Aug; 65(8):1438-45. PubMed ID: 17695281
[TBL] [Abstract][Full Text] [Related]
31. Early cognitive decline in Creutzfeldt-Jakob disease associated with human growth hormone treatment.
Cordery RJ; Hall M; Cipolotti L; Al-Sarraj S; O'Donovan DG; Davidson L; Adlard P; Rossor MN
J Neurol Neurosurg Psychiatry; 2003 Oct; 74(10):1412-6. PubMed ID: 14570836
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of Korean patients with suspected Creutzfeldt-Jakob disease with 14-3-3 protein in cerebrospinal fluid: Preliminary study of the Korean Creutzfeldt-Jakob disease active surveillance program.
Lim JS; Kwon HM; Jang JW; Ju YR; Kim S; Park YH; Park SY; Kim S
Prion; 2015; 9(2):136-43. PubMed ID: 25996401
[TBL] [Abstract][Full Text] [Related]
33. Creutzfeldt-Jakob disease: implications for growth hormone deficient children.
Preece MA
Neuropathol Appl Neurobiol; 1986; 12(5):509-15. PubMed ID: 3537832
[TBL] [Abstract][Full Text] [Related]
34. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients.
Mills JL; Schonberger LB; Wysowski DK; Brown P; Durako SJ; Cox C; Kong F; Fradkin JE
J Pediatr; 2004 Apr; 144(4):430-6. PubMed ID: 15069388
[TBL] [Abstract][Full Text] [Related]
35. Abnormal proteins in the cerebrospinal fluid of a patient with Creutzfeldt-Jakob disease following administration of human pituitary growth hormone.
Macário ME; Moura-Neto V; Vaisman M; Araujo HM; Buescu A; Cordeiro JG; Chagas C
Braz J Med Biol Res; 1992; 25(11):1127-30. PubMed ID: 1342593
[TBL] [Abstract][Full Text] [Related]
36. Analysis of the compliance and the related influence factors in the follow-up process of surveillance for Creutzfeldt-Jakob disease in China.
Zhang XM; Xiao K; Zhou W; Chen C; Lv Y; Chen LN; Shi Q; Dong XP
Prion; 2014; 8(5):359-68. PubMed ID: 25482599
[TBL] [Abstract][Full Text] [Related]
37. Creutzfeldt-Jakob disease surveillance in Australia January 1970 to December 2003.
Klug GM; Lewis V; Boyd A; Lee JS; Masters CL; Collins SJ
Commun Dis Intell Q Rep; 2004; 28(3):356-8. PubMed ID: 15574060
[TBL] [Abstract][Full Text] [Related]
38. The prismatic case of Creutzfeldt-Jakob disease associated with pituitary growth hormone treatment.
Hintz RL
J Clin Endocrinol Metab; 1995 Aug; 80(8):2298-301. PubMed ID: 7629222
[No Abstract] [Full Text] [Related]
39. Absence of evidence of transfusion transmission risk of Creutzfeldt-Jakob disease in the United States: Results froma 28-year lookback study.
Crowder LA; Dodd RY; Schonberger LB
Transfusion; 2024 Jun; 64(6):980-985. PubMed ID: 38650381
[TBL] [Abstract][Full Text] [Related]
40. Creutzfeldt-Jakob disease in Ireland: epidemiological aspects 1980-2002.
Horan G; Keohane C; Molloy S; Howley R; Harney M; Heffernan J; McGuigan C; Hutchinson M; Brett F; Farrell M
Eur Neurol; 2004; 51(3):132-7. PubMed ID: 14988606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
